---

The company leverages technology-supported human data abstraction methods to make sense of complex, fragmented patient data from the real world. Offering quality oncology real-world data from academic and community-based cancer centers and an advanced analytics platform, COTA partners with life sciences companies, providers, and payers to develop fit-for-purpose, regulatory-grade oncology RWD, and data to be used across the drug development lifecycle.

• New York, NY

Related News

• Cota Announces $40 Million Series C Financing to Advance Classification System